Cite
Dechow T, Aldaoud A, Behlendorf T, et al. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. Eur J Haematol. 2021;doi: 10.1111/ejh.13719.
Dechow, T., Aldaoud, A., Behlendorf, T., Knauf, W., Eschenburg, H., Groschek, M., Hansen, R., Söling, U., Grebhardt, S., Siebenbach, H. U., Vannier, C., & Potthoff, K. (2021). Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. European journal of haematology, . https://doi.org/10.1111/ejh.13719
Dechow, Tobias, et al. "Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials." European journal of haematology vol. (2021). doi: https://doi.org/10.1111/ejh.13719
Dechow T, Aldaoud A, Behlendorf T, Knauf W, Eschenburg H, Groschek M, Hansen R, Söling U, Grebhardt S, Siebenbach HU, Vannier C, Potthoff K. Pomalidomide plus dexamethasone for patients with relapsed or refractory multiple myeloma: Final results of the non-interventional study POSEIDON and comparison with the pivotal phase 3 clinical trials. Eur J Haematol. 2021 Oct 29; doi: 10.1111/ejh.13719. Epub 2021 Oct 29. PMID: 34714555.
Copy
Download .nbib